BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$69.13 USD
-1.56 (-2.21%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $69.01 -0.12 (-0.17%) 6:10 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
- YR Estimate
- 12/31/2023
- 12/31/2022
- 12/31/2021
- 12/31/2020
- 12/31/2019
- Revenue - Line of Business (LOBR)
- Revenues: Net product revenues
- 2,372.54
- 2,042.03
- 1,783.50
- 1,805.86
- 1,661.04
- Revenue - Line of Business (LOBR)
- Revenues: Royalty and other revenues
- 46.69
- 54.01
- 62.78
- 54.59
- 43.01
- Revenue - Line of Business (LOBR)
- Revenues: Net Product Revenues: VIMIZIM
- 701.00
- 663.80
- 623.10
- 544.40
- 544.30
- Revenue - Line of Business (LOBR)
- Revenues: Net Product Revenues: VOXZOGO
- 469.90
- 169.10
- 5.86
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Net Product Revenues: NAGLAZYME
- 420.30
- 443.80
- 380.40
- 391.30
- 463.40
- Revenue - Line of Business (LOBR)
- Revenues: Net Product Revenues: PALYNZIQ
- 303.90
- 255.00
- 237.50
- 171.00
- 86.90
- Revenue - Line of Business (LOBR)
- Revenues: Net Product Revenues: KUVAN
- 180.80
- 227.60
- 285.80
- 457.70
- 544.30
- Revenue - Line of Business (LOBR)
- Revenues: Net Product Revenues: BRINEURA
- 161.90
- 154.30
- 128.00
- 110.20
- 72.00
- Revenue - Line of Business (LOBR)
- Revenues: Net Product Revenues: ALDURAZYME
- 131.20
- 128.40
- 122.80
- 130.10
- 97.80